Bayer Aktiengesellschaft (BAYZF)
OTCMKTS · Delayed Price · Currency is USD
53.80
-4.35 (-7.48%)
Feb 18, 2026, 2:08 PM EST
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 9.66B EUR in the quarter ending September 30, 2025, a decrease of -3.09%. This brings the company's revenue in the last twelve months to 45.87B, down -1.87% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
45.87B EUR
Revenue Growth
-1.87%
P/S Ratio
1.06
Revenue / Employee
518.25K EUR
Employees
88,502
Market Cap
57.30B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
| Northwest Biotherapeutics | 937.00K |
Bayer Aktiengesellschaft News
- 1 day ago - Bayer Aktiengesellschaft (BAYRY) Discusses Roundup Class Settlement Agreement and Implications for U.S. Glyphosate Litigation Transcript - Seeking Alpha
- 1 day ago - Bayer agrees to $7.25bn proposed settlement over Roundup weedkiller lawsuits - The Guardian
- 1 day ago - Bayer agrees to US$7.25 billion proposed settlement over thousands of Roundup cancer lawsuits - BNN Bloomberg
- 1 day ago - Bayer offers $7.25bn to settle weedkiller cancer claims - BBC
- 1 day ago - Bayer Proposes New $7 Billion Plan to Settle Roundup Litigation - WSJ
- 1 day ago - Bayer CEO says Roundup settlement is important addition to Supreme Court case - Reuters
- 1 day ago - Bayer (BAYRY) Plans $10.5 Billion Settlement for Roundup Lawsuits - GuruFocus
- 1 day ago - Bayer eyes $10.5B settlement effort to resolve U.S. Roundup litigation - Bloomberg - Seeking Alpha